agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Company profile
Ticker
AGEN
Exchange
Website
CEO
Garo Armen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANTIGENICS INC /DE/
SEC CIK
Corporate docs
IRS number
61562417
AGEN stock data
Latest filings (excl ownership)
8-K
Agenus Reports First Quarter 2024 Results
7 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
7 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
5 Apr 24
EFFECT
Notice of effectiveness
19 Mar 24
S-8
Registration of securities for employees
15 Mar 24
POS AM
Prospectus update (post-effective amendment)
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
Transcripts
AGEN
Earnings call transcript
2024 Q1
7 May 24
AGEN
Earnings call transcript
2023 Q4
14 Mar 24
AGEN
Earnings call transcript
2023 Q3
7 Nov 23
AGEN
Earnings call transcript
2023 Q1
9 May 23
AGEN
Earnings call transcript
2022 Q4
14 Mar 23
AGEN
Earnings call transcript
2022 Q3
8 Nov 22
AGEN
Earnings call transcript
2022 Q2
9 Aug 22
AGEN
Earnings call transcript
2022 Q1
10 May 22
AGEN
Earnings call transcript
2021 Q4
1 Mar 22
AGEN
Earnings call transcript
2021 Q3
9 Nov 21
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 56.53 mm | 56.53 mm | 56.53 mm | 56.53 mm | 56.53 mm | 56.53 mm |
Cash burn (monthly) | 7.75 mm | 9.25 mm | 10.96 mm | 11.51 mm | 12.73 mm | 16.99 mm |
Cash used (since last report) | 12.27 mm | 14.64 mm | 17.35 mm | 18.22 mm | 20.15 mm | 26.90 mm |
Cash remaining | 44.25 mm | 41.89 mm | 39.17 mm | 38.31 mm | 36.37 mm | 29.63 mm |
Runway (months of cash) | 5.7 | 4.5 | 3.6 | 3.3 | 2.9 | 1.7 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 21 |
Closed positions | 59 |
Increased positions | 40 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 100.77 bn |
Total shares | 195.17 mm |
Total puts | 0.00 |
Total calls | 1.70 mm |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Deep Track Capital | 31.70 mm | $26.24 bn |
Vanguard | 30.27 mm | $25.06 bn |
Sofinnova Investments | 15.66 mm | $12.96 bn |
Artal | 15.63 mm | $12.94 mm |
Artal International S.C.A. | 15.63 mm | $0.00 |
INCY Incyte | 12.07 mm | $38.87 mm |
GILD Gilead Sciences | 11.11 mm | $35.78 mm |
STT State Street | 8.68 mm | $7.19 bn |
Larry N Feinberg | 8.42 mm | $27.10 mm |
Renaissance Technologies | 6.03 mm | $5.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 May 24 | Armen Garo H | Common Stock | Grant | Acquire A | No | No | 13.07 | 1,248 | 16.31 k | 71,045 |
19 Apr 24 | Armen Garo H | Common Stock | Grant | Acquire A | No | No | 5.31 | 3,080 | 16.35 k | 69,797 |
5 Apr 24 | Armen Garo H | Common Stock | Grant | Acquire A | No | No | 0.5 | 32,697 | 16.35 k | 1,335,325 |
1 Apr 24 | Wright Timothy | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 14,134.924 | 0.00 | 192,858.238 |
1 Apr 24 | Susan B Hirsch | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 32,039.161 | 0.00 | 95,791.152 |
News
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
16 May 24
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
7 May 24
Agenus Q1 2024 GAAP EPS $(3.04) Beats $(3.14) Estimate, Sales $28.005M Miss $39.268M Estimate
7 May 24
Ligand And Agenus Enter Into $100M Royalty Financing Agreement
7 May 24
12 Health Care Stocks Moving In Friday's Intraday Session
26 Apr 24
Press releases
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
16 May 24
Agenus Reports First Quarter 2024 Results
7 May 24
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
7 May 24
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
1 May 24
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
23 Apr 24